Other Research Trials in New York City

Survey for Caregivers

Are you currently providing care to someone with dementia? Are you employed or were you employed at any point while caring for your friend, family member, or neighbor with Alzheimer’s disease or Dementia? If you answered ‘yes’, then we would love to hear from you!

Researchers at the University at Albany School of Public Health are looking for interested individuals to participate in a study that seeks to understand the experiences of working caregivers. This anonymous survey should take about 10-15 minutes of your time, and can be accessed at the following link:


Participate in a research project on Alzheimer's and Caregiving

The purpose of this project is to identity the types of decisions that caregivers face as their family member or friend progresses through the stages of Alzheimer's.

Learn more

Invitation to participate:

Former caregivers of people with dementia are needed to participate in a research study that will explore the health of caregivers after caregiving ends. Participants will complete an anonymous online survey that will take approximately 20-30 minutes. Participants must (a) be 18 years or older, (b) be a former caregiver of a person with Alzheimer’s disease or any type of dementia, (c) have provided informal, unpaid care for at least 6 consecutive months, and the person who received care must be deceased. You can access the survey by clicking on the link below. Feel free to share or forward the link to individuals who have cared for a person with dementia.

Learn more: https://umassdartmouth.qualtrics.com

Icahn School of Medicine at Mount Sinai

Opportunities to Participate in Research at the Center for Cognitive Neurology


The Alzheimer’s Disease Research Center (ADRC) at the Icahn School of Medicine at Mount Sinai is a comprehensive research facility and clinical program dedicated to the study and treatment of normal aging and Alzheimer’s disease.

View full list

NYU School of Medicine Research Trials

Opportunities to Participate in Research at the Center for Cognitive Neurology


Clinical studies and trials are the force behind the treatment, cure and prevention of any disease. Through the volunteerism of patients and those affected by an illness, knowledge is advanced, and a promise for a cure becomes more of a reality.

View full list

Columbia University Medical Center | Taub Institute

Opportunities to Participate in various research trials


Clinical studies and trials are the force behind the treatment, cure and prevention of any disease. Through the volunteerism of patients and those affected by an illness, knowledge is advanced, and a promise for a cure becomes more of a reality.

View full


What if we could slow the progression of Alzheimer's disease with better sleep?

Recent research suggests there may be a link between sleep, cognitive dysfunction, and Alzheimer’s disease. ReCOGNITION is a research study testing whether an investigational medication, which has sleep promoting effects, can help to slow cognitive deterioration, or improve cognitive function.

We need people to participate in this research study who:

  • Are between 60 to 85 years of age
  • Have been diagnosed with mild dementia due to Alzheimer's disease
  • Do not have an alternative cause for dementia other than Alzheimer's disease
  • Have a caregiver who stays under the same roof at least 3 nights a week and is willing to attend all study visits
  • Click here to find a site near you

Qualified participants will be seen by a doctor and receive all study-related exams, care and medications at no cost. Compensation may be available. This study is sponsored by Neurim Pharmaceuticals (1991) Ltd. Learn more

Cognite Early Stage Alzheimer's Clinical Trial

Imagine making an impact

Consider taking part in a clinical trial that is currently enrolling to treat for early stage Alzheimer’s disease

What is the Cognite Trial?

The Cognite Alzheimer’s Clinical Trial is enrolling men and women who have signs of early stage Alzheimer’s disease. The clinical trial is evaluating whether an investigational combined treatment slows down, arrests, or reverses early stage Alzheimer’s disease.

To qualify, participants must:

  • Be between 55 and 79 years old
  • Have at least 8 years of education
  • Have noticed, or have had a loved one notice, changes in your memory
  • Have noticed changes in their normal, everyday behavior
  • Attend all study visits with a study partner with whom the
    participant has frequent contact
  • Be in good general health

Are you or someone you know experiencing memory loss? Are you or someone you know having trouble retaining information? This may be an indication of early stage Alzheimer’s disease, which is a type of dementia that causes problems with an individual’s memory, thinking, and behavior.

For more information:

646-678-4196 | cognitetrial.com

Learn more (PDF)

Amaranth Study

Clinical Research study for Mild Cognitive Impairment or mild Alzheimer’s disease

SPRI is currently participating in a multi-center, 24-month clinical evaluation of an investigational drug for people suffering from mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). At a minimum, in order to be eligible in this clinical research study, you or someone you know must…

a) be between the ages of 50 and 85 years,
b) been diagnosed with MCI or AD and,
c) have a friend, family member or caregiver who has frequent contact with the participant.

All study-related exams, test, procedures and medication will be provided free of charge. Reasonable compensation of time and travel may be provided.


###Alzheimer's Steadfast Study
You might be eligible to participate in an important research study to determine if the investigational medication, azeliragon (TTP488), slows the progression of Alzheimer’s disease. [Learn more](https://steadfastalzheimers.com/)
###A clinical research study for people with mild-to-moderate Alzheimer’s disease is now enrolling participants.


In this Phase III study, an investigational medication, RVT-101, is being explored as an add-on therapy to donepezil (sometimes known as Aricept®). It is believed that the combination of RVT-101 and donepezil may help with cognition and the ability to perform daily living activities better than donepezil alone.

Contact: (844) 626-4374

Learn more (PDF)

Treatment of Psychosis and Agitation in Alzheimer’s Disease

This research study, funded by the NIH, involves a 12-week double-blind treatment trial in which outpatients with Alzheimer’s disease (age 55-95 years) who have agitation/aggression with or without psychosis (hallucinations or delusions) will receive either low-dose lithium or placebo. Patients are allowed to receive other specific psychiatric medications if needed during the study, and will be closely monitored by physicians who specialize in memory disorders. Patients will receive open treatment with lithium, if clinically indicated, after completing the 12-week double blind trial.
For more information, please contact Jesse Strickler at (646) 774-8668 or strickl@nyspi.columbia.edu.
ClinicalTrials.gov Identifier: NCT02129348

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

The purpose of this study is to evaluate if a change in one’s ability to identify odors may predict improvement in patients with memory loss who are receiving a medicine called donepezil (also known as Aricept). A lack of ability to identify odors may be an early test to determine who is at risk to develop dementia and therefore may help identify who should receive early treatment with donepezil.
For more information, please contact Evan Chunga at (646) 774-7202 or rc2966@cumc.columbia.edu
ClinicalTrials.gov Identifier: NCT01951118